Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Novo Nordisk currently expects an estimated direct, negative low single-digit impact on global sales growth in 2026, after implementing the agreement, the company said
Health Canada says it can now be used to curb heart-attack risk Treatment supports both chronic weight management and to reduce heart risk Health Canada has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of non-fatal heart attack, the drug maker says
Theyll help you create a personalized transition plan, taking into account your current regimen, health history, and other factors
When we supported dozens of patients during their first three months on GLP-1 therapy, clinicians resolved flagged lab changes faster when patients supplied a simple dose and symptom timeline, rather than a scattershot history
This extension of a clinical trial study of 1,961 people followed 327 of them for an additional year
See my options What the current label supports The April 2026 prescribing information describes a 2.5 mg once-weekly starting dose for four weeks, followed by 5 mg once weekly
